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Endothelial progenitor cell (EPC)-capturing techniques have led to revolutionary strategies that can improve the
performance of cardiovascular implant devices and engineered tissues by enhancing re-endothelialization and
angiogenesis. However, these strategies are limited by controversies regarding the phenotypic identities of EPCs
as well as their inability to target and prevent the other afflictions associated with current therapies, namely,
thrombosis and neointimal hyperplasia. Therefore, the goal of this study was to study the efficacy of a bioin-
spired multifunctional nanomatrix in recruiting and promoting the differentiation of EPCs toward an endothelial
lineage. The bioinspired nanomatrix combines multiple components, including self-assembled peptide amphi-
philes (PAs) that include cell adhesive ligands, nitric oxide (NO)-producing donors, and enzyme-mediated
degradable sequences to achieve an endothelium-mimicking character. In this study, human peripheral blood
mononuclear cells (PBMNCs) were isolated and cultured on the bioinspired multifunctional nanomatrix. Initial
cell adhesion, lectin staining, acetylated low-density lipoprotein uptake, and expression of endothelial markers,
including CD31, CD34, von Willebrand Factor, and VEGFR2, were analyzed. The results from this study indicate
that the NO releasing bioinspired multifunctional nanomatrix promotes initial adhesion of EPCs when com-
pared to control surfaces. The expression of endothelial markers is also increased on the bioinspired multi-
functional nanomatrix, suggesting that it directs the differentiation of EPCs toward an endothelial phenotype.
The bioinspired nanomatrix therefore provides a novel biomaterial-based platform for capturing as well as
directing EPC behavior. Therefore, this study has the potential to positively impact the patency of cardiovascular
devices such as stents and vascular grafts as well as enhanced angiogenesis for ischemic or engineered tissues.
Introduction
Endothelial progenitor cells (EPCs) are immaturebone marrow-derived cells that circulate in the blood and
possess the ability to proliferate, migrate, and differentiate
into endothelial cells, but have not yet acquired the charac-
teristics of mature endothelial cells. Currently, VEGFR2/
CD133 or CD34/VEGFR2 double positive cells are com-
monly considered to be EPCs.1–5 EPCs have been found to be
clinically significant in cardiovascular pathologies. They
participate in endothelial homeostasis and promote forma-
tion of new blood vessels.6,7 They are mobilized in cases of
tissue ischemia and home to sites of nascent neovascular-
ization.4 Increased cardiovascular risk factors and devel-
opment of atherosclerosis have been correlated with
reduced EPC circulation.8–10 Significantly, coronary and
arterial pathologies show improvement when treated with
EPC-based therapies.11–14 Since their discovery,5 increasing
attempts have been made to devise therapeutic strategies
utilizing these cells to promote vasculogenesis and re-
endothelialization in ischemic tissues and injured blood
vessels, respectively.
The potential of EPCs gives them an especially great sig-
nificance in cardiovascular implants such as stents, vascular
grafts, and heart valves. The pathophysiology of adverse
events in cardiovascular implant therapies consists of inter-
actions between the cellular components of the blood vessels,
blood, and the components of cardiovascular implants. Gi-
ven the sheer number of these procedures performed every
year, there remains a need to further improve the clinical
performance of these devices. It is widely accepted that the
re-establishment of a healthy endothelium is the ideal ap-
proach to achieve this aim.15 To this effect, several EPC
capture strategies have been explored and they can be
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broadly divided into four categories: antibodies,16–18 pep-
tides,19–21 selectins,2–24 and magnetic molecules.25 These
techniques, especially the use of anti-CD34 antibodies on
metallic stents, have shown great promise.26
Therefore, despite providing evidence for feasibility of
EPC capture techniques, these strategies suffer from several
limitations and unanswered questions.27–29 The safety of
these devices has been questioned, as it was estimated that
99.6% of the cells attracted to anti-CD34 antibodies were not
EPCs.30 Recent studies show that certain populations CD34 +
cells can also differentiate into a smooth muscle cell pheno-
type, which can increase neointimal hyperplasia that is un-
desirable for stent patency.31,32 This is consistent with studies
that show unselected bone marrow cells can differentiate into
smooth muscle cells33 and lead to increased calcification.34 A
similar increase in neointimal proliferation has also been
found with anti-CD34 antibody-coated vascular grafts.35
Therefore, whether this method of EPC capture provides im-
provement over currently available technology has been
questioned. The cause of these limitations can be tracked
down to the controversy regarding the nature and the effec-
tiveness of EPCs. EPCs are currently defined by the presence
of a group of markers, including CD34, CD133, VE-cadherin,
CD31, VEGFR2, and c-Kit.1,3,5,10,36,37 VEGFR2/CD133 or
CD34/VEGFR2 double-positive cells are commonly consid-
ered to be EPCs.1,2,4,5 This lack of clear definition hinders the
development of clear and effective strategies to capture EPCs
and points toward the need for multifunctional strategies. It
also prevents the accurate interpretation of the results from
different studies utilizing different strategies.
Nevertheless, the need for re-establishment of endothe-
lium in cardiovascular implant therapies such as stenting
warrants further research on effective EPC-capturing strate-
gies. The complexity of events that lead to adverse events
such as restenosis and thrombosis, however, necessitate the
successful incorporation of the EPC-capturing technique into
an overall multifunctional strategy that simultaneously pre-
vents all the limitations faced by conventional cardiovascular
implants, including inflammation, restenosis, and thrombo-
sis. Mimicking the native endothelium, which consists of a
layer of endothelial cells lying on a nanofibrillar extracellular
matrix, presents such a strategy that has great potential in
increasing the clinical patency of stents. The endothelium
also releases soluble factors to regulate vascular tone, par-
ticularly nitric oxide (NO), which is critical for maintaining
vascular cell homeostasis.38 The design and development of
biomaterials that mimic the native endothelium can therefore
lead to improved EPC-capturing techniques, which in turn
can result in improved clinical outcomes.
Therefore, the goal of this study is to study the effect of a
bioinspired multifunctional nanomatrix that mimics the na-
tive endothelium on the cellular behavior of EPCs. It is hy-
pothesized that the NO-releasing bioinspired multifunctional
nanomatrix promotes the adhesion and the differentiation of
EPCs toward an endothelial phenotype. The bioinspired
nanomatrix consists of self-assembled peptide amphiphiles
(PAs). PAs are an emerging class of versatile peptide-based
biomaterials that comprise hydrophilic peptide chains co-
valently linked to a hydrophobic alkyl groups. The amphi-
philicity of PAs drives their self-assembly in aqueous media
without the use of organic solvents and therefore extends
their applicability to a variety of implant devices. The pep-
tide sequence allows the incorporation of cellular cues and
therefore allows the design of multifunctional PAs that elicit
specific responses from specific cell types. In this study, the
peptide chain consists of a matrix metalloproteinase-2
(MMP-2) degradable sequence (Gly-Thr-Ala-Gly-Leu-Ile-
Gly-Glu; GTAGLIGQ) linked to either an endothelial cell
adhesive ligand (Tyr-Ile-Gly-Ser-Arg; YIGSR) or an NO-
producing donor polylysine sequence (KKKKK). The MMP-2
degradable sequence allows degradation of the bioinspired
nanomatrix by the cells to promote their migration.39 YIGSR
is derived from laminin, which is a major component of the
endothelial basement membrane. Previous studies have
shown that incorporation of YIGSR promotes the adhesion
and spreading of endothelial cells.40–45 NO is a critical car-
diovascular regulator and is implicated in the mobilization,
recruitment, and differentiation of EPCs.46,47 In native tis-
sues, NO release from the endothelium via endothelial nitric
oxide synthase (eNOS) stimulation has been shown to be the
fundamental step in mobilization of EPCs into circulation.48
However, the understanding of physiological effect of NO on
EPCs remains incomplete. In addition to a biomimetic mul-
tifunctional approach, an added significance of this study is
the attempt to elucidate the potential of NO from donors in
promoting recruitment and differentiation of EPCs, of which
there are no conclusive studies.
In summary, despite the promise of recently developed
strategies to overcome the challenges of current cardiovas-
cular therapies, there remain many emerging concerns and
limited success. It has to be recognized that capturing EPCs
is only the initial aspect of EPC-based therapeutic techniques,
and is therefore critical to develop a multifunctional strategy.
The presence of endothelial cell adhesive ligands, NO-
producing donors, and enzyme-mediated degradable se-
quence endow this nanomatrix with a multifunctional, endo-
thelium-mimicking character as shown in Figure 1. This
nanomatrix is a novel biomaterial-based approach to capturing
EPCs that provides a unique alternative to current techniques.
The significance of this study lies in the design of a strategy to
not just capture the EPCs, but to direct their endothelial dif-
ferentiation, and therefore allowing their integration into the
endothelium. The outcome of this study will also provide
insight into the effect of NO on EPCs. The multifunctional
biomaterial based approach to capturing EPCs will allow the
utilization of the potential of EPCs toward vascularization
of engineered tissues and ischemic tissues. Introduction of
EPCs has shown increased capillary density and improved
left ventricular ejection fraction in myocardial infarction
models,49–51 and increased clinical performance in hind limb
ischemia models,11,12,52 cerebral ischemia model,53 as well as
in diabetic neuropathy.54 However, retention of cells remains
a critical issue, and therefore a bioinspired nanomatrix can
greatly improve the patency of these therapies. This study can
therefore greatly impact the field of cardiovascular therapies
by leading to improved clinical performance.
Materials and Methods
Preparation of a bioinspired multifunctional nanomatrix
The bioinspired nanomatrix was prepared as previously
described.55,56 Briefly, the two PAs, PA-YIGSR (CH3-(CH2)14-
CONH-GTAGLIGQ-YIGSR) and PA-KKKKK (CH3-(CH2)14-
CONH-KKKKK), were synthesized using Fmoc chemistry. The
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peptide chains were first synthesized on an Aapptech Apex
396 peptide synthesizer (Aapptech, KY). They were then al-
kylated with palmitic acid at the N-terminals using a mixture
of o-benzotriazole-N,N,N,N-tetramethyluroniumhexafluoro-
phosphate (HBTU), diisopropylethylamine (DiEA), and di-
methylformamide (DMF). Cleavage was performed with a
cleavage cocktail comprising trifluoroacetic acid, deionized
water, triisopropylsilane, and anisole. The PAs were then
precipitated and lyophilized, and the mass was confirmed via
matrix-assisted laser desorption/ionization–time of flight.
PA-YIGSR contained an MMP-2 degradable sequence
(GTAGLIGQ) linked to an endothelial cell adhesive ligand
(YIGSR). PA-KKKKK contained the MMP-2 degradable
sequence linked to a polylysine NO-producing donor
(KKKKK). The PAs were dissolved in water at a concentra-
tion of 1wt% and a pH of 7. The two PAs were mixed in a 9:1
ratio to form PA-YK.55,56 About 250mL of 0.1wt% PA-YK
was added to each well in a 24-well plate and incubated at
room temperature for 24 h. The increasing concentration of
PA-YK with evaporation of water causes self-assembly of
PA-YK into uniform nanofibers with diameters ranging from
8 to 10 nm. PA-YK was then reacted with pure NO to form
PA-YK-NO. PA-YK-NO was then allowed to self-assemble
by water evaporation to form nanomatrix coatings similar to
PA-YK. In all subsequent experiments, PA-YK served as a
control surface.
Isolation of human endothelial progenitor cells
Human endothelial progenitor cells (EPCs) were obtained
from peripheral blood of healthy, consenting donors as pre-
viously described.11,12 The protocols used in this study have
been approved by the Institutional Review Board (IRB).
Human peripheral blood mononuclear cells (PBMNCs) were
isolated using Histopaque-1077 (Sigma). Fifteen microliters of
2-fold magnetic-activated cell sorting (MACS) buffer diluted
donor blood was added to 15mL of Histopaque-1077 in a
centrifuge tube, and centrifuged at 400 g for 30min at room
temperature. The supernatant was then discarded, and the
opaque interface containing human PBMNCs was transferred
to a new tube and suspended in MACS buffer. After mixing
by gentle pipetting with a Pasteur pipette, the mixture was
centrifuged again. After centrifugation, the supernatant was
discarded, and the cell pellet was resuspended in media.
Isolated human PBMNCs were suspended in endothelial
growth medium-2 Bulletkit, containing endothelial basal
media, 5% fetal bovine serum, human epidermal growth factor,
fibroblast growth factor-B, vascular endothelial growth factor
(VEGF), insulin-like growth factor, and ascorbic acid. Cells
were seeded at a density of 80,000 cells per cm2 on PA-coated
wells (24 well) and incubated at 37C and 5% carbon dioxide.
Evaluation of initial PBMNC adhesion
Human PBMNCs were seeded at 80,000 cells/cm2 on PA-
YK-NO and PA-YK. Tissue culture polystyrene (TCP) was
used as a control surface. To evaluate initial adhesion at 24 h,
the cells were washed three times with phosphate buffered
saline and then stained by 4¢,6-diamidino-2-phenylindole
(DAPI) (Molecular Probes) and imaged by fluorescent mi-
croscopy. The number of cells/cm2 were evaluated by using
the NIS elements imaging software.
FIG. 1. The bioinspired multifunctional nanomatrix is composed of a YIGSR cell adhesive ligand, nitric oxide (NO) pro-
ducing donors and enzyme-mediated degradable sites. The presence of the Tyr-Ile-Gly-Ser-Arg (YIGSR) ligand and NO
release recruit endothelial progenitor cell (EPCs) and promote their differentiation toward an endothelial phenotype. Color
images available online at www.liebertpub.com/tec
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To confirm the endothelial nature of the cells recruited by PA-
YK-NO, theywere subjected to lectin staining and ac-LDLuptake
as previously performed.12 Human PBMNCs were seeded on
PA-YK-NO at 80,000 cells/cm2. PA-YK and TCP were used as
controls. At 7 and 14 days, the cells were incubated in media
containing1,1¢-dioctadecyl-3,3,3¢,3¢-tetramethylindocarbocyanine
labeled acetylated low-density lipoprotein (DiI-Ac-LDL) (Biome-
dical Technologies) for 2h at 37C. Then, the cellswere fixedwith
4% paraformaldehyde. Then, the cells were incubated with 1:200
Fluorescein Isothiocyanate (FITC)-conjugated Ulex Europaeus
Agglutinin-1 Lectin (Sigma) and 1:40,000 DAPI. The cells were
then be imaged and analyzed by NIS elements software. Cells
triple-positive forAc-LDLuptake,Lectin staining, andDAPIwere
imaged as EPCs.
Evaluation of EPC differentiation
Effect of NO released from PA-YK-NO on cell differentia-
tion was studied by analyzing the change in cell surface
markers, including CD45, CD34, CD31, VEGFR2, and von
Willebrand Factor (vWF), using flow cytometry as previously
done.11,12 Human PBMNCs were seeded on PA-YK and PA-
YK-NO. TCPwas used as a control surface. After 7 and 14days
in culture, cells were detached using Accutase and incubated
for 30min at 4C with primary antibodies (FITC-anti-CD45,
Phycoerythrin (PE)-anti-CD34, PE-anti-CD31, PE-anti-
VEGFR2, and PE-anti-vWF). Isotype identical antibodies
served as controls. The cells were fixed in 4% paraformalde-
hyde and subjected to quantitative flow cytometry.
Statistical analysis
Each study was performed independently at least three
times. Statistical significance was obtained by using one-way
analysis of variance (ANOVA) (SPSS) to compare the data.
Within ANOVA, Tukey multiple comparisons test was per-
formed to detect significant differences between pairs. A
value of p < 0.05 was considered to be statistically significant.
FIG. 2. Initial adhesion of EPCs. (A) 4¢,6-diamidino-2-phenylindole staining on Tissue culture plate (TCP), PA-YK, and PA-
YK-NO. Scale bar = 50mm. (B) Quantitative analysis of initial adhesion on TCP, PA-YK and PA-YK-NO. The number of EPCs
was significantly higher on PA-YK-NO and PA-YK when compared to TCP (*p< 0.05). Color images available online at
www.liebertpub.com/tec
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Results and Discussion
The bioinspired multifunctional nanomatrix was prepared
as previously described.55,56 As previously performed,55 the
ratio of PA-YIGSR to PA-KKKKK was optimized based on
endothelial cell adhesion. Briefly, endothelial cells were cul-
tured on increasing ratios of PA-YIGSR and PA-KKKKK and
cell number was evaluated at 4 h. The greatest adhesion was
found on 9:1 mixture of PA-YIGSR and PA-KKKKK. This
was called PA-YK and was reacted with pure NO to obtain
PA-YK-NO. PA-YK-NO is the NO-releasing endothelium-
mimicking nanomatrix. Human EPCs were successfully iso-
lated from the blood of consenting volunteers as described
previously.11,12 The EPCs isolated in this study may be
considered ‘‘early’’ EPCs.57 While ‘‘late’’ EPCs exhibit greater
proliferative capabilities, ‘‘early’’ EPCs show limited prolif-
eration, but greater secretion of pro-angiogenic factors. Initial
cell adhesion was evaluated by staining with DAPI and the
results are shown in Figure 2A. From Figure 2A, it is evident
that there are a greater number of cells with PA-YK-NO and
PA-YK when compared to the uncoated TCP control surface.
After 24 h, cell number was analyzed using NIS Elements
software and these results are shown in Figure 2B. The
number of PBMNCs was significantly higher on PA-YK-NO
and PA-YK when compared to TCP. There was no difference
between PA-YK-NO and PA-YK. This shows that the bioin-
spired nanomatrix has the ability to promote the adhesion of
EPCs. It can also be inferred that the presence of YIGSR cell
adhesive ligand is promoting the adhesion and retention of
these cells.
FIG. 3. UEA-1 Lectin
staining and acetylated low-
density lipoprotein (ac-LDL)
uptake on TCP, PA-YK, and
PA-YK-NO on day 7 (A) and
day 14 (B). Lectin staining
and LDL uptake show that
the cells have an endothelial
character. Scale bar = 50 mm.
Color images available online
at www.liebertpub.com/tec
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To evaluate whether these circulating cells recruited by the
bioinspired nanomatrix possessed endothelial character, they
were assayed for uptake of 1,1¢-dioctadecyl-3,3,3¢,3¢-tetra-
methylindocarbocyanine labeled acetylated low-density li-
poprotein (Dil-ac-LDL) and staining by FITC-conjugated
Ulex Europaeus Agglutinin-1 Lectin. Uptake of ac-LDL and
Ulex lectin staining is characteristic of endothelial cells. As
shown in Figure 3, the cells recruited by the nanomatrices
showed ac-LDL uptake as well as lectin staining at day 7 and
day 14, thereby showing that they possessed endothelial
characteristics. Since these cells were originally PBMNCs that
were recruited, it can be inferred that they were indeed
EPCs. This is a significant result as the population of true
EPCs in peripheral blood is very small. However, in cases of
acute vascular trauma, a 50-fold increase in EPC population
has been reported2 and the recruitment of these cells is crit-
ical for patency of cardiovascular devices.
To further analyze EPC differentiation, the cells were
treated with fluorochrome tagged antibodies for CD31, vWF,
CD34, VEGFR2 and CD45 at days 7 and 14 and analyzed by
flow cytometry. Figure 4 displays the expression of endo-
thelial markers at the 7 day time point while expression of
the same markers at day 14 is shown in Figure 5. CD31,
CD34, VEGFR2, and vWF are endothelial markers. It is evi-
dent that there is an increased expression of these endothelial
markers on PA-YK-NO when compared to controls at day 7
as well as day 14. When quantified, the percentage of cells
expressing CD34, VEGFR2, and vWF was significantly
higher on PA-YK when compared to TCP. However, the
expression of these markers was significantly increased on
PA-YK-NO, the NO releasing bioinspired nanomatrix when
compared to the control substrates, as shown in Figure 5B
(day 14). There was no statistical difference on day 7 (Fig.
4B). This shows that over the 2 weeks, the cells that have
been recruited are directed toward endothelial phenotype.
The expression of VEGFR2 is especially important, as recent
studies show elevated levels of VEGF in cases of acute vas-
cular trauma.2 This is also consistent with the role of VEGF
FIG. 4. (A) Flow cytometric
analysis of endothelial
markers on PA-YK-NO, PA-
YK, and TCP on day 7. (B)
Quantitative analysis of
expression of endothelial
markers on day 7.
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as a promoter of angiogenesis and vasculogenesis via inter-
actions with VEGFR2. VEGF is also thought to regulate the
mobilization of EPCs as evidenced by the correlation of el-
evated blood EPC levels with serum VEGF levels in animal
models and clinical pilot trials.2,58,59 Interestingly, the ex-
pression of CD45 was lower on PA-YK-NO when compared
to control surfaces at day 14. At day 7, there was no differ-
ence in the expression of CD45 on PA-YK-NO when com-
pared to the controls. CD45 is a cell surface marker found
commonly on circulating blood cells and is indicative of an
inflammatory phenotype. From these results, it can be in-
ferred that PA-YK-NO is limiting the differentiation of the
recruited cells into an inflammatory phenotype. This is
consistent with previous studies have shown that NO may
have an anti-inflammatory effect60,61 and therefore contrib-
utes to the patency of PA-YK-NO coated devices.
From these experiments, it is evident that the PA-YK-NO
nanomatrix is promoting the initial adhesion of EPCs and it
is directing the differentiation of these EPCs into an endo-
thelial phenotype. Further, it is clear that the presence of the
YIGSR cell adhesive ligand is promoting the initial cell ad-
hesion of these cells. Previous studies have demonstrated
that laminin derived YIGSR promotes the adhesion and
spreading of endothelial cells.40 However, NO released by
PA-YK-NO is promoting the differentiation of these cells into
an endothelial phenotype. NO is a critical cardiovascular
regulator and it has been shown to positively influence the
recruitment and differentiation of EPCs. More importantly,
the release of NO may promote the mobilization of EPCs
from the bone marrow. While several factors such as G-CSF,
GM-CSF, and VEGF initiate the mobilization of EPCs,7,62,63
NO released by the endothelium via endothelial eNOS has
been shown to be a critical regulator in all their mechanisms
of action.47 Increased NO bioavailability leads to cleavage of
intercellular adhesions between stem cells and stromal cells
of bone marrow by proteinases, causing the mobilization of
FIG. 5. (A) Flow cytometric
analysis of endothelial
markers on PA-YK-NO, PA-
YK, and TCP on day 14. (B)
Quantitative analysis of
expression of endothelial
markers at 14 days.
Expression of von Willebrand
Factor (vWF), VEGFR2, and
CD34 was significantly
higher on PA-YK-NO when
compared to control samples
(*p < 0.05). Expression of
vWF, VEGFR2, and CD34
was significantly higher on
PA-YK when compared to
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EPCs into circulation.48 eNOS transcription enhancer treated
bone marrow cells exhibited improved migration and neo-
vascularization in a hind-limb ischemia model, while the use
of an eNOS inhibitor prevented such function.64 This is also
consistent with cases of impaired eNOS function, as seen in
diabetes mellitus where reduced EPC mobilization has been
observed.65 Thus, mimicking the native endothelium by re-
leasing NO not only recruits and differentiates EPCs; it fur-
ther increases EPC availability for accelerating the process of
endothelialization.
EPC capture strategies have gained attention recently
due to the potential of EPCs to increase clinical patency of
cardiovascular devices. Immobilization of antibodies for
known EPC markers has been the most attractive strategy
so far.18,26 In animal studies, the EPC-capturing stents
demonstrated endothelialization within 24–48 h after im-
plantation, and this allowed earlier discontinuation of anti-
platelet therapy. This technology has been further studied
in clinical studies, and has proven to be feasible.16,66,67 In
one clinical study, it was found that thrombosis was mini-
mal at 30 days and 6 months while neointimal hyperplasia
was seen at rates similar to BMS.16 However, the actual
clinical effectiveness was questioned when a case of rest-
enosis and late stent thrombosis was reported in an EPC
capture stent roughly 5 months after implantation.68 Recent
reports also suggest that while the technology is feasible, it
was lacking in efficacy as it could not prevent neointimal
hyperplasia and restenosis.27–29 These strategies are clearly
limited by the controversy regarding the nature of EPCs and
this underlines the need for further research into character-
ization of EPCs. These strategies also focus on endothelializa-
tion and fail to consider the other limitations of current
devices. This highlights the need for a multifunctional strategy.
Recent studies have attempted a combination of EPC capture
techniques.24,69 In one study, EPC-capturing anti-CD34 anti-
body was used on a sirolimus eluting stent.70 While the results
were promising, the effectiveness of the strategy remains in
doubt.71,72 A bioinspired endothelium mimicking approach
may be able to prevent all the limitations of these devices by
providing the right microenvironment for the adhesion of
specific cell types and by regulating cellular behavior.
In summary, a self-assembled bioinspired multifunctional
nanomatrix has been developed that contains endothelial
cell adhesive ligands, NO producing donors and enzyme-
mediated degradable sites. Previous studies have shown that
this bioinspired nanomatrix releases NO in a desirable bi-
phasic manner,55,56 and previous studies have shown that
the amount of NO released is comparable to cumulative NO
released by endothelial cells.55,73 It promotes the adhesion
and proliferation of endothelial cells, but limits smooth
muscle cell proliferation and platelet adhesion.55,56 This
bioinspired nanomatrix promotes the adhesion of EPCs and
it has been shown to promote endothelial differentiation of
EPCs. In vivo this NO release may therefore promote the
recruitment and differentiation of EPCs, while YIGSR is ex-
pected to improve retention of cells under shear stress. The
novelty of this approach lies in its difference from all other
EPC-capturing strategies as it uses an endothelium mimick-
ing biomaterial to capture EPCs. Further research on EPC
biology is warranted for effective utilization of their potential
and will lead to better and improved EPC-capturing tech-
niques. However, taking into perspective the current ambi-
guity and controversy regarding the phenotypic identity of
EPCs and their potential to differentiate into other cell types,
merely capturing EPCs does not represent the true endpoint
of an EPC based therapy. It is also critical to regulate and
direct the endothelial differentiation of EPCs and promote
their integration into the endothelium. The ability of this
nanomatrix to recruit EPCs and promote their endothelial
differentiation by mimicking the native endothelium is
therefore the true significance of this study. In addition, this
bioinspired nanomatrix allows the successful incorporation
of an EPC based therapy into a multifunctional strategy that
targets all the limitations of current devices including rest-
enosis, thrombosis, and neointimal hyperplasia. The simple
water based self-assembly of the nanomatrix without the use
of organic solvents also allows the extension of EPC based
techniques to the newly developing field of bioabsorbable
stents.74–77 The biomaterial based approach to EPC therapy
also allows the extension of this technology to improve
vascularization of engineered tissues and ischemic tissues.
Angiogenesis remains a critical requirement in cases of is-
chemia, pathologies such as diabetic neuropathy, and tissue
engineered constructs. This nanomatrix therefore has great
potential as a novel biomaterial for a broad range of car-
diovascular applications and it can positively impact the
performance of devices such as stents, vascular grafts, and
heart valves as well as ischemic and engineered tissues
through enhanced angiogenesis.
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